Evidence map›Paper›PMID 38641924›Full record

ArticleJournal of neurochemistry2024

Variant-specific effects of GBA1 mutations on dopaminergic neuron proteostasis.

G Onal, G Yalçın-Çakmaklı, C E Özçelik, I Boussaad, U Ö Ş Şeker, Hugo J R Fernandes, H Demir, R Krüger, B Elibol, S Dökmeci and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Integrated Stress Response Signatures Drive Monocyte Dysfunction inmedRxiv : the preprint server for health sciences · 2025
    Article
  9. Article
  10. Gaucher disease, state of the art and perspectives.Journal of internal medicine · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

G OnalDepartment of Physiology, Anatomy and Genetics, Kavli Institute for NanoScience Discovery, University of Oxford, Oxford, UK.
G Yalçın-ÇakmaklıDepartment of Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
C E ÖzçelikNational Nanotechnology Research Center, UNAM-Institute of Materials Science and Nanotechnology, Bilkent University, Ankara, Turkey.
I BoussaadTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.ORCID 0000-0002-3512-3364
U Ö Ş ŞekerInterdisciplinary Neuroscience Program, National Nanotechnology Research Center, UNAM-Institute of Materials Science and Nanotechnology, Bilkent University, Ankara, Turkey.
Hugo J R FernandesDepartment of Physiology, Anatomy and Genetics, Kavli Institute for NanoScience Discovery, University of Oxford, Oxford, UK.
H DemirDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
R KrügerTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
B ElibolDepartment of Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
S DökmeciDepartment of Medical Biology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
M M SalmanDepartment of Physiology, Anatomy and Genetics, Kavli Institute for NanoScience Discovery, University of Oxford, Oxford, UK.ORCID 0000-0002-5683-1706
Hacettepe University · TRUniversity of Oxford · GBBilkent University · TRCentre Hospitalier de Luxembourg · LUUniversity of Luxembourg · LU

Funding

Biotechnology and Biological Sciences Research Council Pioneer Award BB/Y512874/1Hacettepe University Scientific Research Projects Coordination Unit TSA-2019-17559Medical Research Council (MRC) Career Development Award MR/W027119/1Scientific and Technological Research Council of Turkey (TÜBİTAK) BİDEB 2214-AScientific and Technological Research Council of Turkey (TÜBİTAK) BİDEB 2228-B
6 · The paper itself

Abstract

Glucocerebrosidase 1 (GBA1) mutations are the most important genetic risk factors for Parkinson's disease (PD). Clinically, mild (e.g., p.N370S) and severe (e.g., p.L444P and p.D409H) GBA1 mutations have different PD phenotypes, with differences in age at disease onset, progression, and the severity of motor and non-motor symptoms. We hypothesize that GBA1 mutations cause the accumulation of α-synuclein by affecting the cross-talk between cellular protein degradation mechanisms, leading to neurodegeneration. Accordingly, we tested whether mild and severe GBA1 mutations differentially affect the degradation of α-synuclein via the ubiquitin-proteasome system (UPS), chaperone-mediated autophagy (CMA), and macroautophagy and differentially cause accumulation and/or release of α-synuclein. Our results demonstrate that endoplasmic reticulum (ER) stress and total ubiquitination rates were significantly increased in cells with severe GBA1 mutations. CMA was found to be defective in induced pluripotent stem cell (iPSC)-derived dopaminergic neurons with mild GBA1 mutations, but not in those with severe GBA1 mutations. When examining macroautophagy, we observed reduced formation of autophagosomes in cells with the N370S and D409H GBA1 mutations and impairments in autophagosome-lysosome fusion in cells with the L444P GBA1 mutation. Accordingly, severe GBA1 mutations were found to trigger the accumulation and release of oligomeric α-synuclein in iPSC-derived dopaminergic neurons, primarily as a result of increased ER stress and defective macroautophagy, while mild GBA1 mutations affected CMA, which is mainly responsible for the degradation of the monomeric form of α-synuclein. Overall, our findings provide new insight into the molecular basis of the clinical variability in PD associated with different GBA1 mutations.

Indexed as

alpha-SynucleinDopaminergic NeuronsGlucosylceramidaseInduced Pluripotent Stem CellsMutationProteostasisAutophagyEndoplasmic Reticulum StressHumansParkinson Diseasealpha-SynucleinGBA protein, humanGlucosylceramidaseGaucher diseaseGBA1iPSC‐derived neuronsmacroautophagyParkinson's diseaseα‐Synuclein

Identifiers

PMID38641924
PMCPMC11898552
OpenAlexW4394979756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.